RAVs Frequencies in Boceprevir Combination Treatment
Explore resistance-associated amino acid variants (RAVs) detected during Boceprevir plus PEGINTRON therapy. The study analyzes baseline RAVs in patients achieving sustained virologic response (SVR), RAV decline after treatment lead-ins, and RAV frequencies at virologic failure. Results show varying RAV decline rates in different patients. This research provides valuable insights into RAV dynamics during combination therapy for Hepatitis C.
RAVs Frequencies in Boceprevir Combination Treatment
E N D
Presentation Transcript
Frequencies of Resistance-Associated Amino Acid Variants (RAVs) detected by 454-sequencing during Combination Treatment with Boceprevir Plus PEGINTRON (PegInterferon Alfa-2b)/Ribavirin
454-Sequence analysis of Baseline RAVs in Patients that Achieved SVR (SPRINT-1)
Decline in RAV viral load after 4-week Lead-in (SPRINT-2, RESPOND-2)
RAVs Detected at Baseline Decline Following PegIntron/RBV treatment;Interferon Responsive Patients (SPRINT-2)
RAV Frequencies after 4-week P/R lead-in(SPRINT-2/RESPOND-2)
T54S Variant Detected at Baseline; Interferon Responsive Patient (SPRINT-2)
RAVs Selected at Virologic Failure Decline at Different Rates During Follow-up Period (SPRINT-1)
